Hepatitis D Global Market Report 2025

Hepatitis D, also referred to as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is regarded as the most severe form of viral hepatitis and occurs exclusively in individuals already infected with the hepatitis B virus (HBV). The hepatitis D virus relies on the hepatitis B virus for replication and survival, making it either a co-infection or a superinfection.

The primary types of hepatitis D are acute and chronic. Acute hepatitis D is a sudden and severe liver infection caused by the hepatitis D virus, often leading to rapid-onset symptoms and potential liver complications. Diagnosis is conducted through various methods, including blood tests, elastography, liver biopsy, serologic testing, and other diagnostic techniques. Medications for hepatitis D are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end-users, including clinics, hospitals, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hepatitis D market research report is one of a series of new reports from The Business Research Company that provides hepatitis D market statistics, including the hepatitis D industry global market size, regional shares, competitors with the hepatitis D market share, detailed hepatitis D market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis D industry. This hepatitis D market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hepatitis d market size has grown steadily in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to limited treatment options, high prevalence in endemic regions, co-infection with hepatitis B, low awareness and diagnosis rates, and government vaccination programs.

The hepatitis d market size is expected to see steady growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to expansion of reimbursement policies for novel therapies, and rising investment in the healthcare sector, rising adoption of combination treatments, increasing hepatitis B vaccination coverage, and growing public health initiatives. Major trends in the forecast period include advancements in molecular diagnostic tools, shift toward personalized medicine for liver disease management, development of novel RNA-based therapies, expansion of clinical trials for hepatitis D treatments, and use of telemedicine for hepatitis management.

The forecast of 4.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff-related price increases for pegylated interferon therapies imported from Switzerland may limit treatment availability for this rare condition, leading to unchecked progression to cirrhosis in vulnerable populations. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of hepatitis B is expected to drive the growth of the hepatitis D market in the coming years. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increasing number of hepatitis B cases is attributed to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Hepatitis D depends on the hepatitis B virus for replication, using its surface antigen to infect liver cells, making co-infection with both viruses a significant factor in liver disease progression. For example, in November 2023, the US Department of Health and Human Services reported an 11% rise in newly reported chronic hepatitis B cases in 2022 compared to the previous year. As a result, the growing prevalence of hepatitis B is fueling the expansion of the hepatitis D market.

Leading companies in the hepatitis D market are focusing on developing innovative formulations such as recombinant vaccines to improve immunization efficacy and provide long-lasting protection against the virus. Recombinant vaccines are produced by inserting a gene encoding a viral protein into a host organism, such as bacteria or yeast, allowing the production of the protein to stimulate an immune response without causing the disease. For instance, in December 2022, VBI Vaccines Inc., a US-based biotechnology company, received approval from Health Canada for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], a vaccine for active immunization against all known subtypes of hepatitis B in adults aged 18 and older. This approval also extends to hepatitis D prevention, as the delta agent responsible for hepatitis D cannot exist without a hepatitis B infection. The decision was based on positive results from two pivotal Phase 3 clinical studies, PROTECT and CONSTANT, which demonstrated higher seroprotection rates with PreHevbrio compared to the single-antigen Engerix-B vaccine.

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to advance the development of next-generation antiviral therapies. This collaboration aims to create innovative treatments for serious viral infections, including hepatitis B, herpesviruses, and hepatitis D. Assembly Biosciences Inc. is a US-based biotechnology company specializing in the development of small-molecule therapeutics targeting serious viral diseases, particularly hepatitis B virus (HBV) and herpes viruses.

Major players in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, and Biorex Diagnostics Ltd.

North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis D report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis D market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis D market consists of revenues earned by entities by providing services such as clinical and diagnostic services, public health and awareness campaigns, research and development services, or treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis D market also includes sales of antiviral drugs, interferon therapies, nucleic acid polymers, liver transplant services, and diagnostic tests. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis D Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis d market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis d ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatitis d market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Acute; Chronic
• 2) By Diagnosis: Blood Tests; Elastography; Liver Biopsy; Serologic Testing; Other Diagnosis
• 3) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online Pharmacies
• 4) By End-Users: Clinic; Hospital; Other End Users
• Subsegments:
• 1) By Acute: Self-limiting Acute Hepatitis D; Severe Acute Hepatitis D
• 2) By Chronic: Compensated Chronic Hepatitis D; Decompensated Chronic Hepatitis D
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bristol-Myers Squibb Company; Abbott Laboratories; GSK plc; Gilead Sciences Inc.; Viatris Inc; VBI Vaccines Inc; Alnylam Pharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc.; Dynavax Technologies Corporation; Echosens S.A; Arbutus Biopharma Corporation; PROBIOMED SA de CV; Assembly Biosciences Inc.; Replicor Inc.; Eiger BioPharmaceuticals Inc; Bluejay Therapeutics Inc; Janssen Pharmaceuticals Inc.; Transgene SA; Vir Biotechnology Inc; Biorex Diagnostics Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.